Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients?

Ying X Gue¹, Diana A Gorog^{2

3}, Gregory Y H Lip^{1

4}

Affiliations

¹ Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom (Y.X.G., G.Y.H.L.).
² School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, United Kingdom (D.A.G.).
³ Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom (D.A.G.).
⁴ Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).

Editorial

Ying X Gue et al. Circulation. 2022.

. 2022 Oct 18;146(16):1207-1209.

doi: 10.1161/CIRCULATIONAHA.122.061987. Epub 2022 Aug 27.

Ying X Gue¹, Diana A Gorog^{2

3}, Gregory Y H Lip^{1

4}

¹ Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom (Y.X.G., G.Y.H.L.).
² School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, United Kingdom (D.A.G.).
³ Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom (D.A.G.).
⁴ Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).

No abstract available

Keywords: Editorials; acute coronary syndrome; factor XIa; hemorrhage.

Comment on

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, Hermanides RS, Campo G, Ferreiro JL, Shibasaki T, Mundl H, Alexander JH; PACIFIC AMI Investigators. Rao SV, et al. Circulation. 2022 Oct 18;146(16):1196-1206. doi: 10.1161/CIRCULATIONAHA.122.061612. Epub 2022 Aug 27. Circulation. 2022. PMID: 36030390 Clinical Trial.